InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX Clue Score53
United States Fiscal year ends December CIK 0001819411
$1.64 +1.55% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.64 −74.96% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 18 Mar 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Revenue0.0Operating income−3.5Net income−3.6EPS, diluted−1.33Fiscal year 2021Revenue0.1 +363.7%Operating income−13.8Net income−13.9EPS, diluted−1.37Fiscal year 2022Revenue0.1 −1.0%Operating income−17.8Net income−17.6EPS, diluted−1.48Fiscal year 2023Revenue0.1 −58.4%Operating income−22.3Net income−22.3EPS, diluted−1.71Fiscal year 2024Operating income−20.4Net income−20.4EPS, diluted−0.89Fiscal year 2025Operating income−18.7Net income−20.2EPS, diluted−0.61
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 0.0 0.1 0.1 0.1 n/a n/a
Growth +363.7% −1.0% −58.4%
Operating income −3.5 −13.8 −17.8 −22.3 −20.4 −18.7
Net income −3.6 −13.9 −17.6 −22.3 −20.4 −20.2
Growth
EPS, diluted −1.33 −1.37 −1.48 −1.71 −0.89 −0.61

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2020Operating margin−12,047.5%Net margin−12,387.7%Free cash flow margin−11,291.4%Fiscal year 2021Operating margin−10,323.6%Net margin−10,371.7%Free cash flow margin−9,303.4%Fiscal year 2022Operating margin−13,402.5%Net margin−13,262.0%Free cash flow margin−11,166.4%Fiscal year 2023Operating margin−40,328.3%Net margin−40,354.3%Free cash flow margin−34,217.5%Fiscal year 2024Fiscal year 2025
FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin −12,047.5% −10,323.6% −13,402.5% −40,328.3% n/a n/a
Net margin −12,387.7% −10,371.7% −13,262.0% −40,354.3% n/a n/a
Free cash flow margin −11,291.4% −9,303.4% −11,166.4% −34,217.5% n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−3.2Capital expenditure−0.0Free cash flow−3.3Fiscal year 2021Operating cash flow−12.4Capital expenditure−0.1Free cash flow−12.5Fiscal year 2022Operating cash flow−14.7Capital expenditure−0.1Free cash flow−14.8Fiscal year 2023Operating cash flow−18.9Capital expenditure−0.0Free cash flow−18.9Fiscal year 2024Operating cash flow−18.9Capital expenditure−0.0Free cash flow−18.9Fiscal year 2025Operating cash flow−18.5
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −3.2 −12.4 −14.7 −18.9 −18.9 −18.5
Capital expenditure −0.0 −0.1 −0.1 −0.0 −0.0 n/a
Free cash flow −3.3 −12.5 −14.8 −18.9 −18.9 n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2020Cash7.5Total debt0.7Net cash (debt)6.8Shareholders’ equity6.2Debt to equity0.12Fiscal year 2021Cash36.9Total debt0.7Net cash (debt)36.2Shareholders’ equity34.8Debt to equity0.02Fiscal year 2022Cash7.3Total debt0.6Net cash (debt)6.7Shareholders’ equity18.9Debt to equity0.03Fiscal year 2023Cash11.8Total debt0.6Net cash (debt)11.2Shareholders’ equity12.6Debt to equity0.05Fiscal year 2024Cash10.4Total debt0.4Net cash (debt)9.9Shareholders’ equity7.3Debt to equity0.06Fiscal year 2025Cash20.8Total debt0.4Net cash (debt)20.4Shareholders’ equity18.6Debt to equity0.02
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 7.5 36.9 7.3 11.8 10.4 20.8
Total debt 0.7 0.7 0.6 0.6 0.4 0.4
Net cash (debt) 6.8 36.2 6.7 11.2 9.9 20.4
Shareholders’ equity 6.2 34.8 18.9 12.6 7.3 18.6
Debt to equity 0.12 0.02 0.03 0.05 0.06 0.02

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021† 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024† 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
0.0 0.1 0.1 0.1 n/a n/a
Growth +363.7% −1.0% −58.4%
2.3 7.2 8.4 11.5 10.8 10.2
1.2 6.8 9.5 10.8 9.6 8.5
−3.5 −13.8 −17.8 −22.3 −20.4 −18.7
Growth
−3.6 −13.9 −17.5 −22.2 −19.9 −19.3
0.0 0.0 0.1 0.1 0.5 0.9
−3.6 −13.9 −17.6 −22.3 −20.4 −20.2
Growth
Per share
−1.33 −1.37 −1.48 −1.71 −0.89 −0.61
−1.33 −1.37 −1.48 −1.71 −0.89 −0.61
Growth
2.7 10.2 11.9 13.0 22.9 33.0
2.7 10.2 11.9 13.0 22.9 33.0
Growth +279.1% +16.9% +9.5% +75.9% +44.1%

† The diluted share count jumps at 2021 and 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 6 of 6 years on file.